Osteal Therapeutics Secures $30 Million Series B Financing Led by HM Capital to Advance VT-X7 for Prosthetic Joint Infection

Osteal is a clinical-stage biopharmaceutical company dedicated to developing innovative combination drug-device products for the treatment of infections following artificial joint replacement surgery.According to the company, the funds from this round will be primarily used to advance VT-X7, Osteal Therapeutics’ product for treating periprosthetic joint infection (PJI), into late-stage clinical trials. Following the successful completion of an open-label Phase 2 clinical trial, the company has recently fully initiated patient enrollment for APEX, a randomized controlled clinical trial evaluating VT-X7 in patients with PJI following hip or knee arthroplasty.

Osteal President and CEO David Thompsonstated, “This is an exciting time for us, as we anticipate that Osteal will reach several key value-creation milestones in the coming months. This financing positions us favorably, enabling Osteal not only to continue advancing the VT-X7 program but also to strategically expand our product portfolio based on our technological and scientific expertise.”

Luo Rushu, Founding Managing Partner of HM CAPITALstated: “Osteal is addressing a significant unmet clinical need through highly innovative approaches. HM CAPITAL strongly endorses the capabilities of its team and the positive clinical data achieved to date. We believe that Osteal’s innovative products will significantly improve treatment outcomes and quality of life for patients suffering from severe infections following artificial joint surgery. We look forward to supporting Osteal in achieving multiple key milestone accomplishments over the next 15 months.”

In the United States, more than 40,000 people develop prosthetic joint infections (PJI) each year, a rare but potentially devastating complication following joint replacement surgery. After infecting the prosthetic joint, pathogenic bacteria form biofilm structures that are difficult to eradicate, necessitating prolonged, invasive, and costly treatments. However, these interventions often fail, resulting in high rates of permanent disability and mortality. Recent clinical evidence indicates that the current gold standard for treating PJI—two-stage revision arthroplasty—requires an average of 16 weeks and achieves a success rate of less than 50% at 12 months. This underscores the urgent and unmet clinical need for more effective management of post-arthroplasty infections, highlighting the demand for faster and more reliable therapeutic solutions.

VT-X7 (local irrigation with vancomycin and tobramycin) is an innovative drug-device combination therapy for periprosthetic joint infection (PJI). It delivers high concentrations of mature, broad-spectrum antibiotics—vancomycin and tobramycin—directly into the joint cavity and surrounding tissues affected by postoperative PJI. VT-X7 is a 7-day treatment regimen designed to provide rapid and reliable management of rare but highly threatening infections, thereby addressing an unmet clinical need. In completed Phase II clinical trials, all patients undergoing two-stage revision arthroplasty who received VT-X7 proceeded to reimplantation of the second-stage prosthesis just 7 days after the first-stage explantation and debridement, with 93% of patients remaining infection-free at one year.

Osteal is currently advancing the APEX study, a randomized controlled trial comparing a 7-day VT-X7 regimen for chronic periprosthetic joint infection (PJI) against the current gold standard—two-stage revision arthroplasty over 16 weeks. The FDA has granted VT-X7 Orphan Drug, Fast Track, and Qualified Infectious Disease Product (QIDP) designations. These recognitions underscore a first-in-class, multi-billion-dollar market opportunity. More importantly, VT-X7 has the potential to significantly improve therapeutic outcomes for patients with post-arthroplasty infections who currently respond poorly to existing treatments.

Osteal is a clinical-stage biopharmaceutical company dedicated to developing innovative products for the treatment of infections following artificial joint replacement. The company employs high-concentration, locally delivered antibiotics to treat biofilms formed in prosthetic joint infections (PJI). This approach not only enables rapid resolution of infection but also minimizes systemic side effects on other organs associated with high-dose systemic antibiotic use. Osteal adopts a low-risk development strategy by innovatively repurposing approved drugs with established long-term safety and efficacy profiles for local administration. The company’s lead product, VT-X7, is currently in Phase II clinical development for the treatment of PJI, a serious complication following joint replacement surgery.

HM Capital is a specialized fund focused on healthcare investment. Leveraging the ecosystem advantages of Huimei Medical Group, it invests in the healthcare ecosystem through multi-dimensional and comprehensive approaches, striving to build a professional investment platform with international vision and local execution capabilities. By adopting a dual-currency, multi-strategy fund investment model, HM Capital helps early-stage and growth-stage healthcare companies achieve rapid development.

HM Capital works closely with rapidly growing, innovative healthcare companies. Through its one-stop empowerment platform, HM Capital provides portfolio companies with comprehensive strategic value-added services and systematic support from a global perspective, sharing its worldwide business network and resource ecosystem with exceptional entrepreneurs.